BRI-ROL-001: SV-BR-1-GM Regimen in Combination With Retifanlimab in Patients With Metastatic or Locally Recurrent Breast Cancer Who Have Failed Standard Therapy

Condition: Breast Cancer

Sponsor: BriaCell Therapeutics Corporation

Full Title
BRI-ROL-001: A Phase I/II Study of the SV-BR-1-GM Regimen in Metastatic or Locally Recurrent Breast Cancer Patients in Combination with Retifanlimab

Study Treatment
GM-CSF-secreting breast cancer vaccine SV-BR-1-GM in combination with anti-PD1 immunotherapy retifanlimab-dlwr

Eligibility/Info
Eligible patients will have one of the following prior treatment histories:
- HR+/HER2-: Previously treated with at least 2 prior chemotherapy or targeted therapy regimens
- HER2+: Previously treated with at least 2 anti-HER2 therapies
- TNBC: Exhausted all standard of care therapies known to confer clinical benefit

Contact
For more information you may contact the Research Department through the NYCBS HALO Messaging Center or call directly: 631-675-5075.